TrkB signalling pathway mediates the protective effects of exercise in the diabetic rat retina

Rachael S Allen, Atlanta VA Medical Center
Adam M Hanif, Atlanta VA Medical Center
Marissa A Gogniat, Atlanta VA Medical Center
Brian C Prall, Atlanta VA Medical Center
Raza Haider, Atlanta VA Medical Center
Moe H Aung, Atlanta VA Medical Center
Megan C Prunty, Atlanta VA Medical Center
Lukas M Mees, Atlanta VA Medical Center
Monica M Coulter, Atlanta VA Medical Center
Cara T Motz, Atlanta VA Medical Center

Only first 10 authors above; see publication for full author list.

Journal Title: European Journal of Neuroscience
Volume: Volume 47, Number 10
Publisher: Wiley: 12 months | 2018-05-01, Pages 1254-1265
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1111/ejn.13909
Permanent URL: https://pid.emory.edu/ark:/25593/tqhfm

Final published version: http://dx.doi.org/10.1111/ejn.13909

Copyright information:
© 2018 Federation of European Neuroscience Societies and John Wiley & Sons Ltd

Accessed August 23, 2019 3:14 AM EDT
TrkB signaling pathway mediates the protective effects of exercise in the diabetic rat retina

Rachael S Allen*,a,c, Adam M Hanif*,a, Marissa A Gogniat a,b, Brian C Prall a,b, Raza Haider a, Moe H Aung a,b, Megan C Prunty a, Lukas M Mees a,b, Monica M Coulter a, Cara T Motz a, Jeffrey H Boatright a,b, and Machelle T Pardue a,c

aCenter for Visual and Neurocognitive Rehabilitation, Atlanta VA Medical Center, 1670 Clairmont Road, Decatur, GA, 30033, USA
bDepartment of Ophthalmology, Emory University, 1365 Clifton Road NE, Atlanta, GA, 30322, USA
cDepartment of Biomedical Engineering, Georgia Institute of Technology, 313 Ferst Drive, Atlanta, GA, 30332, USA

Abstract

Diabetic retinopathy is a leading cause of vision loss. Treatment options for early retinopathy are sparse. Exercise protects dying photoreceptors in models of retinal degeneration, thereby preserving vision. We tested the protective effects of exercise on retinal and cognitive deficits in a Type 1 diabetes model and determined whether the TrkB pathway mediates this effect.

Hyperglycemia was induced in Long Evans rats via streptozotocin injection (STZ; 100mg/kg). Following confirmed hyperglycemia, both control and diabetic rats underwent treadmill exercise for 30 minutes, 5 days/week at 0m/min (inactive groups) or 15m/min (active groups) for 8 weeks. A TrkB receptor antagonist (ANA-12), or vehicle, was injected 2.5h before exercise training. We measured spatial frequency and contrast sensitivity using optokinetic tracking biweekly post-STZ; retinal function using electroretinography at 4 and 8 weeks, and cognitive function and exploratory behavior using Y-maze at 8 weeks. Retinal neurotrophin-4 was measured using ELISA.
Compared with non-diabetic controls, diabetic rats showed significantly reduced spatial frequency and contrast sensitivity, delayed electroretinogram oscillatory potential and flicker implicit times, and reduced cognitive function and exploratory behavior. Exercise interventions significantly delayed the appearance of all deficits, except for exploratory behavior. Treatment with ANA-12 significantly reduced this protection, suggesting a TrkB-mediated mechanism. Despite this, no changes in retinal neurotrohin-4 were observed with diabetes or exercise.

Exercise protected against early visual and cognitive dysfunction in diabetic rats, suggesting that exercise interventions started after hyperglycemia diagnosis may be a beneficial treatment. The translational potential is high given that exercise treatment is non-invasive, patient controlled, and inexpensive.

Graphical abstract
STZ-induced diabetic rats undergoing treadmill exercise show reduced visual and retinal dysfunction in early stage disease. Cognitive dysfunction occurred after detection of retinal deficits, but still benefited from the exercise intervention. Treatment with the TrkB antagonist, ANA-12, blocked the protective effects of exercise on retinal and cognitive dysfunction, suggesting that exercise activates a TrkB pathway signaling mechanism.

Keywords
Diabetes; diabetic retinopathy; exercise; TrkB; neurotrophin-4

INTRODUCTION
Diabetes currently affects over 25 million U.S. citizens (CDC 2011 National Diabetes Fact Sheet), and its prevalence is predicted to increase by 35% by 2025 (King et al., 1998). Diabetes is characterized by hyperglycemia, hyperlipidemia, and accompanying inflammation that cause pathologic changes in circulation, leading to vascular damage in the brain, heart, nerves, kidney, and retina (Beisswenger, 1976; Pasquier et al., 2006; Wessels et al., 2006a). One of the most common complications is diabetic retinopathy, which is the leading cause of blindness in working age adults and is characterized by macular edema, retinal ischemia, and abnormal neovascularization (Klein, 2007). Early signs of diabetic retinopathy are found in prediabetic patients (Chen et al., 2012), and diabetic retinopathy may be associated with greater amounts of cerebral ischemia, cortical atrophy, and cognitive deficits (Ferguson et al., 2003; Wessels et al., 2006b; Ding et al., 2010; Haan et al., 2012), suggesting a role for early diabetic retinopathy as a marker or predictor for other diabetic complications. Currently, the leading treatment options for diabetic retinopathy are laser therapy and intravitreal injections of anti-VEGF (vascular endothelial growth factor). Unfortunately both treatments are relatively invasive and are only applicable to later stage diabetic retinopathy, when vascular pathology and loss of visual function are already
advanced (Frank, 2004; Waisbourd et al., 2011). Increasing rates of diabetes combined with a lack of treatment options available until the retinopathy has progressed to its most severe stages highlight the urgent need for new therapies.

Exercise provides protection and promotes neuroregeneration in a variety of neurodegenerative diseases and injury models, and in aging (Speisman et al., 2013; Svensson et al., 2015). In animal models, exercise enhances axon regeneration and reduces neuronal death after peripheral nerve transection (Wood et al., 2012), improves performance on learning and memory tasks (van Praag et al., 1999; Anderson et al., 2000; Radak et al., 2001), and promotes neurogenesis in the central nervous system (van Praag et al., 1999). Exercise also reduces clinical symptoms in amyotrophic lateral sclerosis patients (McCrate & Kaspar, 2008), improves cognitive function in Alzheimer’s patients (Vreugdenhil et al., 2012; Groot et al., 2015), improves motor rehabilitation in stroke patients (Mang et al., 2013), and improves cognitive function in healthy adults (Ploughman, 2008; Chaddock et al., 2010; Erickson et al., 2011; Voss et al., 2013b). In diabetic patients, exercise reduces insulin resistance, ameliorates microvascular dysfunction, and reduces symptoms of neuropathy (Cooper et al., 2016; Billinger et al., 2017; Nuhu & Maharaj, 2017; Sjoberg et al., 2017).

Previously, our group demonstrated that exercise reduces retinal function deficits and photoreceptor cell death in both light-induced (Lawson et al., 2014) and inherited models (Hanif et al., 2015) of retinal degeneration. Exercise also protects against intraocular pressure injury specifically in aged mice (12 months) (Chrysostomou et al., 2014), reduces oxidative stress in the retinas of aged mice (22 months) (Kim et al., 2015), and reduces apoptosis in the diabetic rat retina (Kim et al., 2013). The TrkB (tropomyosin receptor kinase B) pathway may be mediating this protective effect in the retina and other neural tissues (Voss et al., 2013a; Lawson et al., 2014; Leckie et al., 2014; Marosi & Mattson, 2014; Hanif et al., 2015; Chrysostomou et al., 2016). After exercise, local increases occur in neurotrophin-4 (NT-4) (Skup et al., 2002; Cote et al., 2011; Chung et al., 2013) and local and systemic increases occur in brain derived neurotrophic factor (BDNF) (Ploughman et al., 2007; Griffin et al., 2011), the two ligands with the greatest affinity for the TrkB receptor (Barbacid, 1994). To confirm TrkB pathway involvement in exercise protection of retinal degeneration, we treated exercised animals with ANA-12, a TrkB inhibitor that crosses the blood-brain barrier when given systemically and prevents signal transduction and downstream processes (Cazorla et al., 2011a; Cazorla et al., 2011b). We found that blocking the TrkB receptor prevents exercise protection in both inherited and toxic bright light retinal degeneration models (Lawson et al., 2014; Hanif et al., 2015). Our work also showed that animals given exercise treatment after exposure to toxic bright light had higher levels of BDNF in serum, retina, and hippocampus (Lawson et al., 2014).

While exercise has been shown to have protective effects in the retina and in diabetes, the effects of exercise on retinal and visual function in diabetes have not been studied. Here, we tested the protective effects of treadmill exercise treatment in the streptozotocin (STZ) rat model of Type I diabetes. Rats were confirmed to have hyperglycemia prior to exercise treatment to model the clinical scenario of treating a patient newly diagnosed with diabetes. We hypothesized that exercise would reduce early visual and retinal deficits, as measured by
optomotor response (OMR) and electroretinogram (ERG), and early cognitive deficits, as measured by Y-maze. We further hypothesized that because the TrkB pathway mediates the protective effect of exercise in diabetes and in other models of retinal disease, treatment with the TrkB inhibitor ANA-12 would diminish or even prevent this protective effect.

**MATERIALS AND METHODS**

**Animals, diabetes induction, and exercise**

Healthy adult male Long Evans rats (325-350 g; Charles River, Wilmington, MA; n = 120) were housed in shoe-box style cages on a 12:12 light:dark cycle (light onset at 6:00 AM) with chow and water provided ad libitum. Rats were run in sets of 8-12, but Y-maze was not performed on every set of rats. All procedures were approved by the Atlanta Veterans Affairs Institutional Animal Care and Use Committee and conformed to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and the National Institutes of Health guide for the care and use of laboratory animals (NIH Publications No. 8023, revised 1978). During the course of the experiment, 9 diabetic rats died or had to be sacrificed early, 2 control rats died, 6 diabetic rats reverted to non-diabetic status, 2 diabetic rats were excluded from analysis because they had abdominal abscesses, 1 control rat was excluded from analysis due to abnormal ERG function, and 1 control rat was excluded because it was completely unresponsive in OMR testing. Note: both control rat deaths occurred during anesthesia, and we have had no control rat deaths since changing our reversal agent from yohimbine to antisedan (atipamezole).

At approximately 9 weeks of age, hyperglycemia was induced with a single intravenous injection of STZ (100 mg/kg; Sigma-Aldrich, Inc., Milwaukee, WI) dissolved in citrate buffer (pH 4.0). STZ is a toxin that selectively destroys pancreatic beta cells – the cells that produce insulin to regulate blood glucose levels – making it useful in creating animal models of Type I diabetes. Diabetes mellitus (DM) was defined as two successive daily blood glucose levels higher than 250 mg/dL (freestyle handheld blood glucose meter from tail-prick blood), measured 2-3 days after STZ injection. Body weights and blood glucose were monitored twice per week. If body weight decrease approached a 10% loss, diabetic rats were treated with small pellets of sustained-release subcutaneous insulin (Linplant; Linshin Canada, Scarborough, ON, Canada) at a dose sufficient to prevent excessive weight loss and catabolic response, but not enough to control hyperglycemia (Thule et al., 2006).

Rats confirmed to be diabetic were assigned to one of four groups: inactive+vehicle, active +vehicle, inactive+ANA-12, and active+ANA-12. Non-diabetic control rats were assigned to the same four groups, although significant differences among control groups were not observed for any of the functional parameters studied. Thus, the control groups have been combined and are referred to as “non-diabetic controls”).

Exercise treatment started 3 days post-STZ injection after hyperglycemia was confirmed and continued to 8 weeks post-STZ when rats were euthanized via decapitation (due to future analysis for catecholamines in the brain). Active rats were exercised on rodent treadmills with shock detection (Exer-3/6; Columbus Instruments, Columbus, OH) five times per week for 30 minutes at a rate of 15 m/min. Rats received a maximum of 10 shocks from an
electrified grid (1 Hz, 0.46 mA) if they stepped off the moving belt during exercise sessions. Rats learned to run on the treadmill very easily, and rarely received shocks after the first week. Inactive rats followed an identical regimen, with the exception that their treadmills were stationary (Acclimation Cage-2; Columbus Instruments, Columbus, OH).

To explore the role of TrkB pathway signaling in exercise protection, rats were given intraperitoneal injections of either vehicle (VEH) (1% DMSO, 16.5% CremophorEL; 16.5% ethanol, 66% Dulbecco’s PBS, pH 7.4) or ANA-12 in vehicle (0.2 mg/kg body weight; Sigma-Aldrich Inc., Milwaukee, WI), which readily crosses the blood-brain barrier and selectively inhibits the TrkB receptor (Cazorla et al., 2011a). Based on previously characterized pharmacokinetics of ANA-12 (Cazorla et al., 2011a), rats were injected 2.5 hours before each exercise session to align peak TrkB inhibition with exercise.

Animals received visual acuity and contrast sensitivity testing one week prior to the beginning of the experiment, and were tested at 2, 4, 6 and 8 weeks afterward in the same manner. Additionally, animals underwent ERG recordings at the 4 and 8 week time points to assess retinal function and Y-maze at the 8 week time point to assess cognitive function and exploratory behavior. A subset of animals (n = 12/group) received Y-maze at 4, 6, and 8 weeks in conjunction with OMR testing in order to determine the temporal appearance of visual vs. cognitive dysfunction. All animals were given ear tags for IDs that did not reveal their designated group. While the diabetic and control rats could be differentiated easily by their weights, whether the rats received exercise or ANA-12 treatment was hidden from the tester.

**Assessment of Visual Function – Optomotor Response**

Visual function was tested using the virtual optokinetic system (OptoMotry system; Cerebral Mechanics, Lethbridge, AB, Canada), as previously described (Douglas et al., 2005). Briefly, an unrestrained rat was placed on a platform at the center of a virtual-reality chamber composed of four computer monitors that display vertical sine wave gratings rotating at 12 deg/s. A video camera positioned above the animal was used to watch in real time for the presence or absence of reflexive head movements (tracking) in response to the projected gratings rotating in the same direction. The experimenter manually tracked the head of the rat to align the center of the virtual cylinder with the viewing position of the rat. During visual acuity assessment, the grating started at a spatial frequency of 0.042 cyc/deg with 100% contrast. The acuity threshold was determined automatically by the OMR software using a staircase paradigm based on observations of head-tracking reflexes. Similarly, the contrast sensitivity threshold was determined by reducing the contrast of the black and white gradients from 100% in a staircase paradigm until animal head-tracking movements were no longer observed. Contrast sensitivity was measured at the spatial frequency of 0.064 cyc/deg for the study. This was the spatial frequency that elicited the maximum sensitivity obtained from the rats at baseline when a contrast sensitivity curve was assessed across five spatial frequencies, as previously described (Aung et al., 2013). Contrast sensitivity was calculated as a reciprocal of the Michelson contrast from the screen’s luminance (i.e. [maximum + minimum]/[maximum-minimum]), as previously described (Prusky et al., 2006). Spatial frequency and contrast sensitivity thresholds from 0 to 8 weeks...
were normalized to control rat values and each rat’s individual baseline. For optomotor
response, the following animal numbers were tested: non-diabetic control (n = 35-37), DM
+inactive+VEH (n = 16-17), DM+active+VEH (n = 16-19), DM+inactive+ANA (n = 10),
and DM+active+ANA (n = 9-11). Numbers vary due to some animals not being tested at all
timepoints.

Assessment of Retinal Function – Electroretinogram (ERG)
Rats were dark-adapted overnight and then prepared under dim red illumination, as
previously described (Ciavatta et al., 2009). Briefly, rats were anesthetized (ketamine [60
mg/kg] and xylazine [7.5 mg/kg]), and the corneal surface anesthetized (0.5% tetracaine
HCl) and pupils dilated (1% tropicamide). Electrical responses were recorded to flash
stimuli presented in order of increasing luminance using a signal-averaging system (UTAS
BigShot; LKC Technologies, Gaithersburg, MD) via a gold loop electrode contacting the
cornea. ERG stimuli consisted of a 6-step protocol of flash stimuli. Five sequential dark-
adapted responses were recorded (scotopic: −3.0 to 2.1 log cd s/m²) to isolate rod-dominated
and mixed rod and cone responses. Then, rats were exposed to a steady background adapting
field (30 cd/m²) for 10 min to saturate the rod photoreceptors and isolate cone pathway
function. After the light-adaptation period, animals were presented with 2.0 log cd s/m²
flicker stimuli at 6 Hz in the presence of the background light. Responses were recorded
using the same signal averaging system (UTAS bigShot; LKC Technologies). After testing,
rats received yohimbine (2.1 mg/kg) to reverse the effects of xylazine and to prevent corneal
ulcers (Turner & Albassam, 2005).

ERG data were analyzed offline. For dark adapted ERG responses, amplitudes and implicit
times were measured for a-waves, b-waves, and oscillatory potentials (OPs). OPs were
digitally filtered using the ERG system software (75-500 Hz; EM Version 8.1.2, 2008; LKC
Technologies). For light adapted ERG responses, flicker response amplitudes and implicit
times were measured from the trough of the signal after the flash onset to the peak.
Oscillatory potentials (OPs) were analyzed for two flash stimuli: −1.9 and 0.7 log cd s/m²,
which we have previously shown to distinguish rod vs. rod-cone pathway dysfunction in
early diabetes, respectively (Aung et al., 2013; Pardue et al., 2014). OP implicit times were
reported normalized to control values at each time point. For ERG, the following animal
numbers were tested: non-diabetic control (n = 32-40), DM+inactive+VEH (n = 20-23), DM
+active+VEH (n = 17-21), DM+inactive+ANA (n = 10), and DM+active+ANA (n = 9-10).
Numbers vary due to some animals not being tested at all timepoints.

Analysis of cognitive and exploratory behavior – Y-maze
The Y-maze (San Diego Instruments, San Diego, CA) was used to assess spatial working
memory, based on the methods of Maurice and colleagues (Maurice et al., 1995). Briefly,
each rat was placed in one arm of the Y-maze and permitted to explore the entire maze freely
for 8 minutes. The series of arm entries was monitored visually and recorded. One correct
alternation was defined as entering the 3 arms consecutively (for example, the pattern
ABCACB would have 3 correct alternations – ABC, BCA, and ACB). The percentage of
correct spatial alternation was calculated as the number of correct alternations/(total number
of arm entries −2) × 100. Additionally, the total number of arm entries was recorded as a
measure of exploratory behavior. For Y-maze, the following animal numbers were tested: non-diabetic control (n = 24), DM+inactive+VEH (n = 20), DM+active+VEH (n = 7), DM+inactive+ANA (n = 7), and DM+active+ANA (n = 7).

Analysis of NT-4 levels in the retina – ELISA (enzyme-linked immunoabsorbent assay)

Rats were euthanized via decapitation at 8 weeks post-STZ, and their retinas were removed and snap frozen. To perform tissue lysate extraction, individual retinas were re-suspended in approximately 10 weight/volume ratio of acid-extraction buffer containing protease inhibitors (50 mmol/L sodium acetate, 1 mol/L NaCl, 0.1% Triton X-100, pH 4, Roche Complete Mini Protease Inhibitors, Catalog Number 11836153001) and sonicated using an ultrasonic processor. Homogenates were kept on ice for 30 minutes; sonication and incubation on ice was repeated. The homogenates were then centrifuged for 30 minutes at 15,000 g and 4°C and the supernatant was transferred to a new tube. Total protein concentration was measured using a BCA protein assay kit (Pierce BCA Protein Assay Kit, Catalog Number PI23225) and the absorbance was measured at 562 nm using BioTek Synergy 2 plate reader.

A commercial ELISA kit was used to assess the NT-4 levels in retina samples [Biosensis Neurotrophin 4/5 Rapid ELISA Kit: Human, Monkey, Rat, and Mouse (2 Plates), Catalog Number BEK-2211-2P]. NT-4 standards (100 μL of 15.6 – 1000 pg/mL) and retina samples (100 μL, diluted 1:2) were run in triplicates according to the manufacturer’s instructions. The absorbance was measured at 450 nm using a BioTek Synergy 2 plate reader. The sample concentration was determined from the standard concentration and absorbance measurements with a four-parameter non-linear regression using Gen5 software. Results were expressed as concentration of NT-4 (pg/mg). Note: ELISA results were added to this study many months after the initial tissue harvesting, and thus, not all retinal samples had detectable levels of protein. Retinal numbers were as follows: non-diabetic controls (n = 11), DM+inactive+VEH (n = 12), DM+active+VEH (n = 8), DM+inactive+ANA (n = 8), and DM+active+ANA (n = 8).

Statistical analysis

Results are expressed as mean ± standard error of the mean (SEM). Weight, OMR, and ERG were analyzed using a two-way repeated measures ANOVA followed by Holms-Sidak post hoc comparisons (SigmaPlot version X; Systat Software, Inc.; San Jose, CA). Blood glucose and Y-maze (both spatial alternation and exploratory behavior) were analyzed using a one-way ANOVA followed by Holms-Sidak tests for individual comparisons. Chi-square was used to compared the categorical data on survival, reversion to non-diabetic state and need for insulin. Non-diabetic control groups were combined when no statistical differences were found between groups for any of our functional measures, including OMR (contrast sensitivity and spatial frequency), ERG (oscillatory potentials and flicker), y-maze (spatial alternation and exploratory behavior), and blood glucose (p = 0.706 for contrast sensitivity, our most sensitive measure). Animals numbers (n) are occasionally reported as a range because some animals did not survive for the full experiment.
RESULTS

Diabetic rats showed reduced body weight and increased blood glucose

In order to evaluate the systemic effects of exercise on diabetes, we measured body weight and blood glucose. All four diabetic rat groups (DM+inactive+VEH, DM+active+VEH, DM+inactive+ANA, and DM+active+ANA) showed significant reductions in body weight compared with non-diabetic controls beginning at 4 weeks post-STZ (p < 0.002) and continuing to 8 weeks (p < 0.001), similar to previous studies using STZ-induced diabetes (Aung et al., 2013) [Repeated measures ANOVA interaction effect, F(28, 559) = 5.638, p < 0.001] (Fig. 1A). Weights from diabetic groups that were exercised and/or received ANA-12 did not differ significantly from each other. All four diabetic groups, regardless of exercise or ANA-12 treatments, showed blood glucose levels of >250 mg/dL beginning the first week post-STZ. Blood glucose averaged across 8 weeks was significantly higher in all four diabetic groups compared with non-diabetic controls [ANOVA, F(4, 78) = 251.778, p < 0.001](Fig. 1B) and did not show any differences with exercise and/or ANA-12 treatment.

Weights and blood glucose were not affected by exercise treatment (Fig. 1). While not significant, diabetic rats that received exercise showed a trend for lower death rates (7.69%) than DM+inactive groups (12.82%; combination of DM+inactive+VEH and DM+inactive+ANA) or DM+active+ANA (18.18%; Table 1; Chi-square = 0.08, p = 0.960) and appeared less likely to need an insulin intervention (57.69%) than DM+inactive (64.7%) or DM+active+ANA (70.00%) groups (Table 1; Chi-square = 0.70, p = 0.704). DM+active+VEH rats also showed an increased likelihood (15.38%) of reverting to a non-diabetic state after two consecutive high blood glucose readings (>250 mg/dL) than DM+inactive (5.13%) or DM+active+ANA (0%) groups (Table 1; Chi-square = 12.90, p = 0.002). This reversion usually occurred between 1-4 weeks post-STZ injection. Despite a propensity to revert to a non-diabetic state, DM+active+VEH rats that maintained hyperglycemia did not show reduced blood glucose levels compared with other diabetic groups (Fig. 1B).

Protective effects of exercise on spatial frequency and contrast sensitivity deficits are blocked by treatment with ANA-12

Beginning at 4 weeks post-STZ, DM rats showed a significant difference in spatial frequency thresholds depending on whether they received exercise and/or ANA-12 [Two-way repeated ANOVA interaction effect F(16, 456) = 12.974, p < 0.001]. DM+inactive+VEH rats showed significant reductions in spatial frequency thresholds compared with non-diabetic controls (at 4 weeks, p = 0.004). Exercised diabetic rats (DM+active+VEH) exhibited preserved visual acuity with spatial frequency thresholds significantly higher than those of DM+inactive+VEH rats (at 8 weeks, values normalized to non-diabetic controls and each animal’s individual baseline: DM+active+VEH: 0.94±0.02; DM+inactive+VEH: 0.82±0.03; p < 0.001). Daily injections of ANA-12 blocked the protective effects of exercise such that spatial frequency thresholds of DM+active+ANA rats were statistically indistinguishable from DM+inactive+VEH thresholds between 4 and 8 weeks post-diabetic induction (at 8 weeks, values normalized to non-diabetic controls and each animal’s individual baseline: DM+inactive+VEH: 0.82±0.03; DM+active+ANA: 0.76±0.03; p = 0.076) (Fig. 2A).
Similarly, beginning at 4 weeks post-STZ, DM+inactive+VEH rats showed significant reductions in contrast sensitivity compared with non-diabetic controls (Two-way repeated ANOVA interaction effect $F(16, 456) = 8.179$, $p < 0.001$; post-hoc comparison: $p < 0.001$). Beginning at 4 weeks, exercise preserved contrast sensitivity in diabetic rats with contrast sensitivity thresholds significantly higher in DM+active+VEH rats compared to DM +inactive+VEH ($p = 0.002$). ANA-12 treatment abolished this effect such that DM+active +ANA rats had contrast sensitivity thresholds significantly lower than DM+active+VEH rats (at 4 weeks; $p = 0.003$). In fact, DM+active+ANA contrast sensitivity thresholds were statistically equivalent to the contrast sensitivity thresholds of the DM+inactive+VEH group at all relevant time points (at 8 weeks: normalized value for DM+inactive+VEH: 0.62±0.03; DM+active+ANA: 0.74±0.08, $p = 0.160$) (Fig. 2B).

**Protective effects of exercise on ERG OPs and flicker implicit times are blocked by treatment with ANA-12**

Representative OP waveforms showed delays in inactive diabetic rats that were not observed in diabetic rats that received exercise. ANA-12 treatment blocked this protection (Fig. 3A). When quantified, OP2 implicit time (flash intensity $-1.9 \log \text{ cd m}^{-2}$) was significantly delayed at 4 and 8 weeks post-STZ in all 4 diabetic rat groups compared with non-diabetic controls (Fig. 3C; Two-way repeated ANOVA interaction effect $F(4,191) = 3.544$, $p = 0.01$). This difference was measureable at 4-weeks post-STZ ($p < 0.001$). By 8 weeks, however, diabetic rats assigned to exercise treatment showed significant improvements in OP2 implicit time delays compared with inactive rats, (DM+inactive+VEH rats 1.14±0.02 vs. DM+active +VEH 1.07±0.01, normalized to control; post hoc comparison, $p < 0.001$). Treatment with ANA-12 abolished this protective effect, such that DM+active+ANA rats (1.17±0.02) were statistically indistinguishable from DM+inactive+VEH rats (Fig. 3C). Amplitudes and implicit times for OP1, 3, and 4 were also analyzed and showed the same implicit time delays with diabetes and attenuation with exercise (data not shown); OP2 is shown here because it has the best signal to noise ratio.

At 4 weeks, ERG flicker amplitudes and implicit times were not different between the treatment groups. At 8 weeks, representative flicker waveforms showed delays in inactive diabetic rats that were not observed in diabetic rats that received exercise. ANA-12 treatment blocked this protection (Fig. 3B). When 8 week data was quantified, DM+inactive+VEH rats exhibited significant delays in ERG flicker implicit times (57.0±0.6 ms) compared to non-diabetic control rats (Fig. 3D; 53.1±0.5 ms; One-way ANOVA $F(4, 92) = 12.407$, $p < 0.001$; posthoc comparison, $p < 0.001$). Exercise maintained the flicker implicit times in DM +active+VEH rats, which were statistically indistinguishable from non-diabetic controls and had significantly faster flicker implicit times than DM+inactive+VEH rats (53.3±0.9 vs. 57.0±0.6 ms, $p < 0.001$). In contrast, active diabetic rats injected daily with ANA-12 had 8-week flicker implicit times that were indistinguishable from the inactive diabetic rats, and thus, were significantly slower than those of the DM+active+VEH group (DM+active+ANA: 58.4±1.5 ms; Fig. 3D).
A- and b-wave amplitudes and implicit times, oscillatory potential amplitudes, and flicker amplitudes were also analyzed, but the results were not significantly different between treatment groups (data not shown).

Exercise reduced cognitive function deficits in diabetic rats but did not change exploratory behavior; ANA-12 blocked protection

At 8 weeks post-STZ, inactive diabetic rats showed significant reductions in spatial alternation compared to non-diabetic controls (values normalized to non-diabetic controls: 1.01±0.03; DM+inactive+VEH: 0.85±0.04, One-way ANOVA, F(4,64) = 5.429, p < 0.001; post-hoc comparison p = 0.002). With exercise treatment, these cognitive deficits were not observed in diabetic rats (DM+active+VEH normalized values: 1.04±0.06, p = 0.007). Furthermore, treatment with ANA-12 abolished the protective effects of exercise on cognitive deficits (DM+active+ANA12 normalized values: 0.77±0.06, p = 0.021) (Fig. 4A). For exploratory behavior, diabetic groups showed reductions in number of entries on Y-maze compared with non-diabetic controls, but neither exercise nor ANA-12 injections altered the magnitude of these deficits (One-way ANOVA, F(4,64) = 4.665, p = 0.002) (Fig. 4B).

Effects of diabetes and exercise on visual and cognitive deficits

In a subset of the inactive diabetic animals presented above, we performed Y-maze tests at 4 and 6 weeks, in addition to 8 weeks, so that we could compare cognitive function to 4, 6, and 8 week visual function results. The earliest significant deficits in visual function were in contrast sensitivity at 4 weeks post-STZ (Two-way repeated ANOVA Interaction effect, F(2, 61) = 13.192, p < 0.001; post-hoc comparison p = 0.046). Meanwhile, significant cognitive deficits, measured as spatial alternation on Y-maze, did not appear until 6 weeks (Two-way repeated ANOVA Main effect, F(1, 50) = 7.505, p = 0.01; post-hoc comparison p = 0.027) (Fig. 5A).

Exercise interventions in diabetic rats reduced functional deficits on a variety of tests: OMR (both spatial frequency and contrast sensitivity), ERG (both oscillatory potential and flicker implicit times), and Y-maze (spatial alternation only). In Figure 5B, we compare exercise efficacy for each of these five parameters as a percent of the control values for the 8-week data in DM+inactive+VEH and DM+active+VEH rats. Contrast sensitivity showed the largest percent difference in active versus inactive animals (24%; Fig. 5B). However, Y-maze and flicker implicit time, while exhibiting smaller changes in percent difference, were completely preserved with exercise, having functional scores that were maintained at control levels (Fig. 5B).

Retinal NT-4 levels did not change significantly with diabetes or exercise

NT-4 ELISAs were performed on retinas from diabetic rats and non-diabetic controls at 8 weeks post-STZ. No differences in NT-4 levels were observed in any treatment group relative to non-diabetic controls (Fig. 6).
DISCUSSION

Exercise was found to be neuroprotective against early deficits in visual and cognitive function in diabetic rats that exhibited confirmed hyperglycemia prior to exercise treatment. The delayed appearance of retinal deficits in diabetic rats with exercise was blocked using ANA-12, an antagonist that binds to the TrkB receptor and blocks signal transduction, suggesting that the TrkB pathway is critical for exercise protection in diabetes.

Early retinal and cognitive deficits with hyperglycemia

We observed early retinal deficits in STZ-induced diabetic rats, including spatial frequency and contrast sensitivity deficits at 4 weeks post-STZ, delays in oscillatory potential implicit time at 4 weeks, and delays in flicker implicit time at 8 weeks. Similar to previous reports from our lab and others (Barber, 2003; Antonetti et al., 2006; Aung et al., 2013; Pardue et al., 2014), these functional deficits occurred early in the disease, well before acellular capillaries and pericyte dropout are observed in the retina (6-8 months) (Kern et al., 2010). While others have observed decreases in a- and b-wave responses at similar time points post-STZ (Li et al., 2002; Ly et al., 2011), in our hands, the STZ rat model does not show consistent changes in a- and b-wave amplitude or implicit time (Aung et al., 2013; Aung et al., 2014; Pardue et al., 2014). We only see consistent changes in OP implicit times, with the dim flash responses showing delays before the bright flash responses, and light-adapted flicker implicit times (Aung et al., 2013; Pardue et al., 2014).

Using a Y-maze test to assess spatial alternation, we observed early cognitive deficits with hyperglycemia at 8 weeks post-STZ. Cognitive deficits have been reported previously with diabetes, both in STZ-induced and high fat diet models (Reisi et al., 2009; Datusalia & Sharma, 2014; Klein et al., 2016; Underwood & Thompson, 2016). In order to determine whether retinal or cognitive deficits presented first, we performed OMR and Y-maze testing at 4, 6, and 8 weeks in a subset of rats. We chose to use contrast sensitivity on OMR as our measure of retinal function because it showed the greatest deficit. Deficits in contrast sensitivity appeared prior to Y-maze deficits (4 weeks vs. 6 weeks) (Fig. 5A). Additionally, deficits in contrast sensitivity were more severe than Y-maze deficits (55% vs. 84%) (Fig. 5A). Taken together, these results suggest that the retina is affected early in diabetes and could be used as an early biomarker for the extent of diabetic injury to the brain.

Exercise protected against retinal and cognitive deficits in diabetic rats

Previously, exercise treatment has been shown to be protective in a variety of retinal disease models, including light induced retinal degeneration (Lawson et al., 2014), the rd10 model of retinal degeneration (Hanif et al., 2015), intraocular pressure injury of ganglion cells (Chrysostomou et al., 2014), natural aging (Kim et al., 2015), and diabetes (Kim et al., 2013). While treadmill exercise was shown to reduce apoptosis (Kim et al., 2013) and VEGF expression (Ji et al., 2013) in the retina of STZ-induced diabetic rats, the effects of exercise on retinal function deficits were not investigated. Here, we showed that exercise treatment in STZ-induced diabetes resulted in delayed appearance of deficits in spatial frequency and contrast sensitivity as measured by OMR and reduced delays in implicit time for oscillatory potentials and flicker ERG. We focused on functional rather than histological results in this
paper because visual function had yet to be investigated with respect to diabetic retinopathy and exercise and because cell death has primarily been reported after the latest time point investigated here (8 weeks) (Barber \textit{et al}., 2005; Gastinger \textit{et al}., 2006; Kern & Barber, 2008; Adamiec-Mroczek \textit{et al}., 2015), though increases in caspase-3 and other apoptotic proteins have been reported as early as 2-4 weeks (Barber \textit{et al}., 2005; Li \textit{et al}., 2008; Adamiec-Mroczek \textit{et al}., 2015). Interestingly, the exercise protection observed here and elsewhere in diabetic retinopathy coupled with our earlier work on the protective effects of exercise in retinal degeneration models may reflect a generalized protective mechanism to retinal neuronal dysfunction and cell loss rather than a disease-specific treatment. In these experiments, exercise did not provide complete protection from diabetic retinopathy, but rather induced significant delays in the observed dysfunction by several weeks (Fig. 2 for spatial frequency and contrast sensitivity thresholds). It is not known from this dataset if the exercised animals would have sustained benefit with disease progression. Future studies could expose diabetic rats to exercise for a longer period (6-8 months) to determine the long-term effects.

Exercise has been shown previously to be protective against diabetes-induced cognitive deficits, as measured by Morris Water Maze (Reisi \textit{et al}., 2009; Klein \textit{et al}., 2016). Our finding that exercise reduced Y-maze deficits after diabetes confirmed these results. Interestingly, exercise reduced spatial alternation deficits on Y-maze, but not exploratory behavior deficits, perhaps because retinal and spatial memory defects share a neuronal origin, while exploratory behavior deficits are more an indicator of overall systemic disease (i.e., diabetic rats not moving around as much due to general sickness behavior). It is possible that visual improvements with exercise are due to an enhancement of brain function by exercise. However, given that exercise protection in the retina (using ERG) is observed prior to exercise protection in the brain, the retinal protection appears to be, at least in part, tissue specific.

In order to determine which functional responses were most impacted by the effects of exercise, we compared exercise protection on a variety of tests. We found that while contrast sensitivity showed the greatest difference in active vs. inactive rats, flicker implicit time and Y-maze scores for active rats reached control levels (Fig. 5B). In addition, diabetic rats receiving exercise showed a significant increase in the propensity to revert to a non-diabetic state, while there was a non-significant trend towards reduced death rates and a reduced need for insulin intervention. Previous studies have demonstrated a protective effect of exercise on mortality related to cardiovascular fitness in diabetic animals (Souza \textit{et al}., 2007) and people (Wei \textit{et al}., 2000), as well as a reduced need for insulin use in women with gestational diabetes (Brankston \textit{et al}., 2004). However, while exercise has been shown to reduce insulin resistance, hyperglycemia, and HbA1c in diabetic patients, we observed no differences in weight and blood glucose between our exercised diabetic group and any other diabetic group.
TrkB pathway signaling mediates the protective effects of exercise in both the retina and the brain

A number of studies point to the TrkB signal transduction pathway and its ligands as a mediator of exercise’s protective effects (Ploughman et al., 2007; Griffin et al., 2011; Voss et al., 2013a; Lawson et al., 2014; Leckie et al., 2014; Marosi & Mattson, 2014; Hanif et al., 2015; Chrysostomou et al., 2016). Inhibiting the TrkB pathway via ANA-12, which prevents ligands from binding to the TrkB receptor, blocked exercise’s protective effects in light-induced and hereditary models of retinal degeneration (Lawson et al., 2014; Hanif et al., 2015). Many exercise studies highlight BDNF as the protection-mediating ligand, including previous work by our group demonstrating that mice undergoing treadmill exercise following light-induced retinal degeneration exhibit higher levels of BDNF in the retina, hippocampus, and serum (Lawson et al., 2014). However, rats express higher levels of NT-4 in addition to BDNF in healthy spinal cord after treadmill exercise (Skup et al., 2002) and in injured spinal cord after bike exercise (Cote et al., 2011). Additionally, exercise protection after peripheral nerve injury is blocked in NT-4/5 knockout mice (English et al., 2011). These studies suggest that both NT-4 and BDNF could be upregulated with exercise.

In this study, we investigated TrkB pathway activation and NT-4 in the diabetic retina with and without exercise treatment. Treating active diabetic rats with the TrkB inhibitor, ANA-12, abolished the protective effects of exercise on both retinal and cognitive function. Specifically, active diabetic rats that received ANA-12 showed no benefit to spatial frequency and contrast sensitivity decreased thresholds, oscillatory potential and flicker implicit time delays, or spatial alternation deficits on Y-maze. In sum, these results suggest that TrkB signaling plays a role in mediating the protective effects of exercise in the diabetic retina and brain and demonstrates that ANA-12 can block the effects of exercise on both vision and cognition simultaneously.

It is interesting to speculate on the precise mechanism by which the TrkB pathway is mediating exercise protection in the retina. TrkB receptor expression has been localized to a number of retinal layers, including the retinal pigmented epithelium, outer plexiform layer, inner nuclear layer, inner plexiform layer, retinal ganglion cell layer, and in Müller cells in rodents exposed to light damage and dopaminergic amacrine cells (Cellerino & Kohler, 1997; Asai et al., 2007; Saito et al., 2009). TrKB’s truncated isoform, which is also capable of acting as a signaling receptor, has been observed in Müller cells of normal rats as well (Berk et al., 2015). Additionally, the TrKB inhibitor ANA-12 has been shown to reduce phosphorylated TrkB, phosphorylated ERK1/2, and Akt signaling in the retina, demonstrating that TrkB signaling occurs in the retina (Mazzaro et al., 2016; Daly et al., 2017).

NT-4 is widely expressed in the retina and has been identified in the inner and outer nuclear layers (Ghazi-Nouri et al., 2003), retinal ganglion cells (Ghazi-Nouri et al., 2008), photoreceptor outer segments (Ghazi-Nouri et al., 2008), and in Müller cells during proliferative vitreoretinopathy (Ghazi-Nouri et al., 2008). Additionally, NT-4 was shown to rescue neurons in retinal explants from STZ diabetic rats (Oshitari et al., 2011; Oshitari et al., 2014), and both NT-4 and BDNF protect against retinal ganglion cell death in an optic nerve transection model when administered intraocularly (Peinado-Ramon et al., 1996).
However, NT-4 levels did not show significant differences in diabetic animals, regardless of whether animals were given exercise treatment or ANA-12 (Fig. 6). These results suggest that the TrkB signaling underlying the protective effects of exercise on the retina may involve other neurotrophins besides NT-4.

Ligands other than NT-4 (BDNF, neurotrophin-3, nerve growth factor) are also capable of activating the TrkB receptor and could be involved in mediating the protective effects of exercise (Reichardt, 2006). The protective effects of exercise are pleitropic. In injury models outside the retina, exercise’s effects have been shown to affect neurotrophins differently in different tissue types (Keeler et al., 2012) and even different cell types (Skup et al., 2002). For example, when looking at exercise’s effects on the spinal cord, NT-4 expression was increased more in astrocytes and BDNF expression was increased more in neurons (Skup et al., 2002). Expression patterns of neurotrophins also differ based on injury type (Omura et al., 2005) and exercise type (Cote et al., 2011). Future research could investigate precisely where the TrkB pathway and neurotrophic factors are acting in the retina and how these actions are changing with different diseases and with exercise treatment.

**Translation of exercise as a treatment in clinical diabetes**

Exercise is an exciting treatment option for diabetic patients because it is non-invasive, can be started early on in the disease, and causes changes in retinal, visual, and cognitive function. In this study, exercise treatment was begun in rats shortly after the onset of diabetes. The fact that we used a treatment prevention protocol (exercise begins after confirmed hyperglycemia) as opposed to a preconditioning protocol (exercise begins prior to diabetes induction) is a critical distinction that makes these experiments more clinically relevant. Future studies should investigate the effects of implementing an exercise program at later time points (for example, after clear visual and retinal deficits have occurred, but prior to any vascular pathology), which would make this research even more applicable to clinical diabetes.

The exercise paradigm used here would be very manageable for patients: 30 minutes of exercise, 5 times a week at a rate of 15 m/min. The speed used here appears to translate to a purposeful walking speed in humans. If patients were informed that even walking has a substantial protective effect - that they aren’t expected to immediately shift from a sedentary lifestyle to running marathons - they might be more inclined to incorporate an exercise program into their lifestyle and treatment plan. Indirect evidence has shown that glycemic control and a healthy lifestyle (which includes exercise) decreases the risk of retinopathy (Loprinzi et al., 2014; Aiello et al., 2015; Bener et al., 2016). Research on exercise in diabetic and prediabetic patients is already being conducted to investigate insulin resistance, cognitive function, and conversion from prediabetes to diabetes, among other conditions (Anderson-Hanley et al., 2012; Fiocco et al., 2013; Davy et al., 2017; Nuhu & Maharaj, 2017; Rowan et al., 2017; Sjoberg et al., 2017). These studies would benefit from adding retinal pathology and visual function to the parameters investigated, as the retina may provide a window into some of the earliest functional deficits in diabetes as well as the earliest protection with exercise.
Conclusions

Exercise reduced early retinal and visual dysfunction in a rat model of Type I diabetes when implemented after the onset of hyperglycemia. Exercise also reduced deficits in cognitive function but did not change exploratory behavior. Exercise protection for retinal, visual, and cognitive function is blocked with ANA-12, suggesting a role for TrkB pathway signaling in mediating exercise’s protective effects in both the retina and the brain. Changes in retinal NT-4 were not observed with diabetes or exercise, suggesting other TrkB ligands may be involved. Future research is needed to define Trk-B pathway involvement in exercise-mediated protection in diabetes.

Acknowledgments

This work was supported by the National Institutes of Health [grant numbers P30 EY006360, R01 EY014026, and T32 EY007092-27]; the Rehabilitation R&D Service of the Department of Veterans Affairs (Merit Award I01RX000951 and Research Career Scientist Award to MTP), Research to Prevent Blindness, and the Abraham J. and Phyllis Katz Foundation.

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>BDNF</td>
<td>Brain-derived neurotrophic factor</td>
</tr>
<tr>
<td>CS</td>
<td>Contrast sensitivity</td>
</tr>
<tr>
<td>DM</td>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme-linked immunoabsorbent assay</td>
</tr>
<tr>
<td>ERG</td>
<td>Electroretinogram</td>
</tr>
<tr>
<td>IT</td>
<td>Implicit Time</td>
</tr>
<tr>
<td>NT-4</td>
<td>Neurotrophin-4</td>
</tr>
<tr>
<td>OMR</td>
<td>Optomotor response</td>
</tr>
<tr>
<td>OP</td>
<td>Oscillatory potential</td>
</tr>
<tr>
<td>SF</td>
<td>Spatial frequency</td>
</tr>
<tr>
<td>STZ</td>
<td>Streptozotocin</td>
</tr>
<tr>
<td>TrkB</td>
<td>Tropomyosin receptor kinase B</td>
</tr>
<tr>
<td>VEGF</td>
<td>Vascular endothelial growth factor</td>
</tr>
<tr>
<td>VEH</td>
<td>Vehicle</td>
</tr>
</tbody>
</table>

References


Figure 1. Reduced weight and increased blood glucose in all four diabetic groups compared with non-diabetic controls
A) Weight for weeks 1-8 post-STZ. Each animal’s weights were normalized to its baseline weight, which for diabetic rats is a week 0 weight taken prior to STZ injection. B) Average blood glucose (mg/dL) at 8 weeks post-STZ. *** p < 0.001. Results expressed as means ± SEM with scatter plot.
Figure 2. Protective effects of exercise on spatial frequency and contrast sensitivity thresholds in diabetic rats are blocked by the TrkB antagonist, ANA-12

A) Spatial frequency thresholds for weeks 0 to 8 post-STZ, normalized to control rat values and each rat’s individual baseline. B) Contrast sensitivity thresholds from 0 to 8 weeks post-STZ, normalized to control rat values and each rat’s individual baseline. Black asterisks indicate comparisons of non-diabetic controls to DM+inactive+VEH, DM+inactive+ANA, and DM+active+ANA groups; green asterisks indicate comparisons of DM+active+VEH group to all other DM groups (DM+inactive+VEH, DM+inactive+ANA, and DM+active +ANA); light green asterisks indicate comparisons of DM+active+VEH to both inactive DM groups (DM+inactive+VEH and DM+inactive+ANA); orange asterisks indicate comparisons of non-diabetic controls to DM+active+VEH group; light blue asterisks indicate comparisons of non-diabetic controls to DM+active+ANA and DM+inactive+VEH groups. *** p < 0.001, ** p < 0.01, * p < 0.05. Results expressed as means ± SEM.
Figure 3. Exercise protects ERG OP2 and flicker implicit times through TrkB pathway signaling

A) Representative OP waveforms at 8 weeks post-STZ in response to −1.9 log cd s/m² flash stimuli showed OP2 delays in DM+inactive+VEH, DM+inactive+ANA, and DM+active+ANA (arrowheads) compared to non-diabetic controls and DM+active+VEH (indicated by vertical gray line). B) Representative flicker ERG waveforms from rats at 8 weeks post-STZ showed similar delays as the OPs. The vertical gray line indicates the flicker b-wave peak and the arrowheads mark delayed waves. C) OP2 implicit times for weeks 4-8 post-STZ, normalized to non-diabetic control rat values. D) Flicker ERG implicit times at 8 weeks post-STZ. Black asterisks indicate comparisons of non-diabetic controls to all diabetic
groups; green asterisks indicate comparisons of DM+active+VEH group to DM+inactive +VEH, DM+inactive+ANA, and DM+active+ANA groups. *** p < 0.001, ** p < 0.01. Results expressed as means ± SEM.
Figure 4. Beneficial effects of exercise on cognitive function deficits, but not exploratory deficits
A) Cognitive function at 8 weeks post-STZ as measured by spatial alternation on Y-maze (values normalized to control). Black asterisks indicate a comparison of Non-diabetic controls to DM+inactive+VEH and DM+active+ANA groups. Green asterisks indicate a comparison of DM+active+VEH group to DM+inactive+VEH, and DM+active+ANA groups. ** p < 0.01. Results expressed as means ± SEM.

B) Exploratory behavior at 8 weeks post-STZ as measured by # of entries (number of entries) on Y-maze (values normalized to control). Gray asterisks indicate a comparison to Non-diabetic controls. ** p < 0.01. Results expressed as means ± SEM.
Figure 5. Effects of diabetes and exercise on visual and cognitive deficits in rats
A) Diabetes resulted in deficits in cognitive function as measured by spatial alternation on Y-maze and retinal function as measured by contrast sensitivity on OMR at 4, 6, and 8 weeks (values expressed as % control). Black asterisks indicate a comparison to Non-diabetic controls. B) A summary of the protective effects of exercise on visual and cognitive deficits when comparing inactive vs. active diabetic rats (values are expressed as % control and represent 8 week data for all tests). Green asterisks indicate a comparison of DM+active +VEH group to DM+inactive+VEH group. *** p < 0.001, ** p < 0.01, * p < 0.05. SF = spatial frequency, CS = contrast sensitivity, OP IT = oscillatory potential implicit time, Flicker IT = flicker implicit time. Results expressed as means ± SEM.
Figure 6. Retinal NT-4 levels did not change significantly with diabetes or exercise. Retinal NT-4 levels at 8 weeks post-STZ. Results expressed as means ± SEM.
Table 1
Death rates, reversion to a non-diabetic state, and need for insulin intervention in active and inactive diabetic rats

Inactive includes DM+inactive+VEH rats.

<table>
<thead>
<tr>
<th></th>
<th>Inactive (n=34)</th>
<th>Active (n=26)</th>
<th>Active + ANA (n=11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of rats that died/were sacrificed</td>
<td>14.71%</td>
<td>7.69%</td>
<td>18.18%</td>
</tr>
<tr>
<td>% of rats that reverted to non-diabetic state</td>
<td>5.88%</td>
<td>15.38%</td>
<td>0.00%</td>
</tr>
<tr>
<td>% of rats that needed insulin</td>
<td>75.86%</td>
<td>57.69%</td>
<td>70.00%</td>
</tr>
</tbody>
</table>

Note: once diabetic rats reverted to a non-diabetic state, they were excluded from the study.

* Chi-square p=0.002.